The specialist engages academic centers, biopharma, clinical diagnostics labs, and emerging clinical partners to drive technology evaluation, workflow adoption, and clinical implementation. They serve as a trusted advisor to key decision-makers, collaborate closely with cross-functional teams, and play a critical role in achieving regional revenue growth and strategic market expansion for the oncology segment in APAC.
Duties include, but are not limited to:
· Develop and execute segment focused strategic account and territory plans with territory account managers to achieve or exceed revenue targets
· Accelerate opportunities across academic research, translational labs, biopharma, and oncology testing providers
· Partner with Account Managers, Field Application Scientists, and Customer Care to ensure seamless customer experience
· Manage pipeline and forecasting using CRM tools; track progress and analyse performance metrics
· Build and maintain relationships with key opinion leaders (KOLs), senior scientists, clinicians, pathologists, and decision-makers
· Provide consultative guidance on study design, workflows, assay development, clinical validation, and bioinformatics analysis
· Stay current on oncology research trends, clinical, regulatory, operational, and commercial dynamics that shape adoption decisions
· Represent ONT at conferences, symposia, and customer events; deliver seminars, workshops, and technical briefings
· Partner with Marketing, Business Development, Inside Sales, and FAS teams to execute segment-specific go-to-market plans
· Align with Field Marketing, Product Management, and Inside Sales to refine messaging, content, and campaigns for the oncology audience
· Deliver structured customer and market feedback to inform product roadmap and commercial strategy
Preferred Background
· MSc or PhD in Genomics, Molecular Biology, Immunology, Cell Biology, or related field.
· Regional cancer research and oncology testing market knowledge.
· 8+ years of genomics/commercial experience, preferably in oncology or sequencing-based diagnostics
· Proven track record selling complex research technologies (e.g., NGS, multi-omics platforms) and oncology testing solutions (germline + somatic)
· Strong network and experience engaging KOLs, senior researchers, clinicians, and lab directors across leading academic and clinical centers
· Deep understanding of oncology research trends, clinical workflows, regulatory and reimbursement environments
· Strategic, analytical, and consultative selling mindset with strong influence and negotiation capabilities
· Excellent communication and presentation skills across scientific and business audiences
· Experience using CRM tools (e.g., Salesforce)
· Ability to travel up to ~70% across the APAC region
#LI-MW1
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
